Have a personal or library account? Click to login
Depression and Oxidative Stress Interaction in Stable Coronary Heart Disease Cover

References

  1. Adifbair, A., Saleem, M., Lanctôt, K., Herrmann, N. (2016). Potential biomarkers for depression associated with coronary artery disease: A critical review. Curr. Mol. Med., 16, 137–164.10.2174/1566524016666160126144143
  2. Antoniades, C., Antonopoulos, A. S., Bendall, J. K., Channon, K. M. (2009). Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr. Pharm. Des., 15 (3), 329–342.10.2174/138161209787354230
  3. Bal, N., Acar, S. T., Yazıcı, A., Yazıcı, K., Tamer, L. (2012). Altered levels of malondialdehyde and vitamin E in major depressive disorder and generalized anxiety disorder. J. Psychiatry Neurol. Sci., 25 (3), 206–211.
  4. Barth, J., Schumacher, M., Herrmann-Lingen, C. (2004). Depression as a risk factor for mortality in patients with coronary heart disease: A meta-analysis. Psychosom. Med., 66 (6), 802–813.10.1097/01.psy.0000146332.53619.b2
  5. Bauer, L. K., Caro, M. A., Beach, S. R., Mastromauro, C. A., Lenihan, E., Januzzi, J. L., Huffman, J. C. (2012). Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Amer. J. Cardiol., 109 (9), 1266–1271.10.1016/j.amjcard.2011.12.017
  6. Black, C. N., Bot, M., Scheffer, P. G., Cuijpers, P., Penninx, B. W. (2015). Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology, 51, 164–175.10.1016/j.psyneuen.2014.09.025
  7. Brouns, R., Verkerk, R., Aerts, T., Surgeloose D., Wauters, A., Scharpé, S., De Deyn, P. P. (2010). The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem. Res., 35 (9), 1315–1322.10.1007/s11064-010-0187-2
  8. Brown, A. D., Barton, D. A., Lambert, G. W. (2009). Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs, 23 (7), 583–602.10.2165/00023210-200923070-00004
  9. Huffman, J. C., Mastromauro, C. A., Sowden, G. L., Wittmann, C., Rodman, R., Januzzi, J. L. (2011). A collaborative care depression management program for cardiac inpatients: Depression characteristics and in-hospital outcomes. Psychosomatics, 52 (1), 26–33.10.1016/j.psym.2010.11.021
  10. Carney, R. M., Freedland, K. E. (2008). Depression in patients with coronary heart disease. Amer. J. Med., 121 (11, Suppl 2), S20–S27.10.1016/j.amjmed.2008.09.010
  11. Cassano, P., Fava, M. (2002). Depression and public health: An overview. J. Psychosom. Res., 53 (4), 849–857.10.1016/S0022-3999(02)00304-5
  12. Celano, C. M., Huffman, J. C. (2011). Depression and cardiac disease: A review. Cardiol. Rev., 19 (3), 130–142.10.1097/CRD.0b013e31820e810621464641
  13. Chauvet-Géliniera, J. C., Trojak B., Vergès-Patois B., Cottin Y., Bonin B. (2013). Review on depression and coronary heart disease. Arch. Cardiovasc. Dis., 106 (2), 103–110.10.1016/j.acvd.2012.12.00423527914
  14. Cheraghi, M., Ahmadvand, H., Maleki, A., Babaeenezhad, E., Shakiba, S., Hassanzadeh, F., (2019). Oxidative stress status and liver markers in coronary heart disease. Rep. Biochem. Mol. Biol., 8 (1), 49–55.
  15. Cumurcu, B. E., Ozyurt, H., Etikan I., Demir S., Karlidag R. (2009). Total antioxidant capacity and total oxidant status in patients with major depression: Impact of antidepressant treatment. Psychiatry Clin. Neurosci., 63 (5), 639–645.10.1111/j.1440-1819.2009.02004.x19674383
  16. De Hert, M., Detraux, J., Vancampfort, D. (2018). The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin. Neurosci., 20 (1), 31–40.10.31887/DCNS.2018.20.1/mdehert
  17. Dhama, K., Latheef, S. K., Dadar, M., Samad, H. A., Munjal, A., Khandia, R., Karthik, K., Tiwari, R., Yatoo, M. I., Bhatt, P., Chakraborty, S., Singh, K. P., Iqbal, H., Chaicumpa, W., Joshi, S. K. (2019). Biomarkers in stress related diseases/disorders: Diagnostic, prognostic, and therapeutic values. Front Mol. Biosci., 6,p.91.10.3389/fmolb.2019.00091684307431750312
  18. Dhar, A. K., Barton, D. A. (2016). Depression and the link with cardiovascular disease. Front Psychiatry, 7, 33.10.3389/fpsyt.2016.00033480017227047396
  19. Ērglis, A., Dzērve-Tāluts, V., Bajāre, I. (2020). Latvijas iedzīvotāju kardiovaskulāro un citu neinfekcijas slimību riska faktoru šķērsgriezuma pētījums [Cross-sectional study of cardiovascular and noninfectious diseases risk factors among Latvia’s inhabitants]. Latvijas Universitātes Kardioloģijas un reģeneratīvās medicīnas zinātniskais institūts, Rīga. 13 pp. (in Latvian). https://esparveselibu.lv/sites/default/files/2020-10/LATVIJAS%20IEDZĪVOTĀJU%20KARDIOVASKULĀRO%20%20UN%20CITU%20NEINFEKCIJAS%20SLIMĪBU%20RISKA%20FAKTORU%20ŠĶĒRSGRIEZUMA%20PĒTĪJUMS%20.pdf (accessed 12.03.2022).
  20. Feng, Z., Hu, W., Marnett, L. J., Tang, M. S. (2006). Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutat. Res., 601 (1–2), 125–136.10.1016/j.mrfmmm.2006.06.00316872641
  21. Frasure-Smith, N., Lespérance, F. (2010). Depression and cardiac risk: Present status and future directions. Heart, 96 (3), 173–176.10.1136/hrt.2009.18695719861300
  22. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392 (10159), 1789–1858.
  23. Glassman, A. H., Bigger, J. T., Gaffney, M., Shapiro, A. P., Swenson, J. R. (2006). Onset of major depression associated with acute coronary syndromes: Relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch. Gen. Psychiatry, 63 (3), 283–288.10.1001/archpsyc.63.3.28316520433
  24. Goodman, J., Shimbo D., Haas, D. C., Davidson, K. W., Rieckmann, N. (2008). Incident and recurrent major depressive disorder and coronary artery disease severity in acute coronary syndrome patients. J. Psychiatr. Res., 42 (8), 670–675.10.1016/j.jpsychires.2007.07.004239872017709116
  25. Guck, T. P., Kavan, M. G., Elsasser, G. N., Barone, E. J. (2011). Assessment and treatment of depression following myocardial infarction. Amer. Fam. Physician, 64 (4), 641–648.
  26. Halaris, A. (2017). Inflammation-associated co-morbidity between depression and cardiovascular disease. Curr. Top Behav. Neurosci., 31, 45–70.10.1007/7854_2016_2827830572
  27. Hasnain, M., Vieweg, W. V., Lesnefsky, E. J., Pandurangi, A. K. (2011). Depression screening in patients with coronary heart disease: A critical evaluation of the AHA guidelines. J. Psychosom. Res., 71 (1), 6–12.10.1016/j.jpsychores.2010.10.00921665006
  28. Huffman, J. C., Celano, C. M., Beach, S. R., Motiwala, S. R., Januzzi, J. L. (2013). Depression and cardiac disease: Epidemiology, mechanisms, and diagnosis. Cardiovasc. Psychiatry Neurol., 2013, 695925.10.1155/2013/695925
  29. Januzzi, J. L., Jr, Stern, T. A., Pasternak, R. C., DeSanctis, R. W. (2000). The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch. Intern. Med., 160 (13), 1913–1921.10.1001/archinte.160.13.191310888966
  30. Jeon, S. W., Kim, Y. K. (2017). Inflammation-induced depression: Its patho-physiology and therapeutic implications. J. Neuroimmunol., 313, 92–98.10.1016/j.jneuroim.2017.10.01629153615
  31. Jiang, W., Krishnan, R., Kuchibhatla, M., Cuffe, M. S., Martsberger, C., Arias, R. M., O’Connor, C. M., SADHART-CHF Investigators (2011). Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Amer. J. Cardiol., 107 (4), 545–551.10.1016/j.amjcard.2010.10.013307363021295172
  32. Kander, M. C., Cui, Y., Liu, Z. (2017). Gender difference in oxidative stress: A new look at the mechanisms for cardiovascular diseases. J. Cell Mol. Med., 21 (5), 1024–1032.10.1111/jcmm.13038538716927957792
  33. Kaya, Y., Çebı, A., Söylemez, N., Demır, H., Alp, H. H., Bakan, E. (2012). Correlations between oxidative DNA damage, oxidative stress and coen-zyme Q10 in patients with coronary artery disease. Int. J. Med. Sci., 9 (8), 621–626.10.7150/ijms.4768346584523055813
  34. Khandaker, G. M., Zuber, V., Rees, J., Carvalho, L., Mason, A. M., Foley, C. N., Gkatzionis, A., Jones, P. B., Burgess, S. (2020). Shared mechanisms between coronary heart disease and depression: Findings from a large UK general population-based cohort. Mol. Psychiatry, 25 (7), 1477–1486.10.1038/s41380-019-0395-3730300930886334
  35. Khawaja, I. S., Westermeyer, J. J.., Gajwani, P., Feinstein, R. E. (2009). Depression and coronary artery disease: The association, mechanisms, and therapeutic implications. Psychiatry (Edgmont), 6 (1), 38–51.
  36. Kuller, L. H., Arnold, A. M., Psaty, B. M., Robbins, J. A., O’Leary, D. H., Tracy, R. P., Burke, G. L., Manolio, T. A., Chaves, P. H. M. (2006). 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch. Intern. Med., 166 (1), 71–78.10.1001/archinte.166.1.7116401813
  37. Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M. A., van Zyl, L. T., Baker, B., Swenson, J. R., Ghatavi, K., Abramson, B. L., Dorian, P., Guertin, M. C., CREATE Investigators (2007). Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA, 297 (4), 367–379.10.1001/jama.297.4.36717244833
  38. Lin, D., Wang, L., Yan, S., Zhang, Q., Zhang, J. H., Shao, A. (2019). The role of oxidative stress in common risk factors and mechanisms of cardiocerebrovascular ischemia and depression. Oxid. Med. Cell Longev., 2019, 2491927.10.1155/2019/2491927
  39. Liu, T., Zhong S., Liao, X., Chen J., He, T., Lai, S., Jia Y. (2015). A meta-analysis of oxidative stress markers in depression. PLoS One, 10 (10), e0138904.10.1145/2818302
  40. Maes, M., Galecki, P., Chang, Y. S., Berk, M. (2011). A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry, 35 (3), 676–692.10.1016/j.pnpbp.2010.05.00420471444
  41. Matthews, K. A., Schott, L. L., Bromberger, J. T., Cyranowski, J. M., Everson-Rose, S. A., Sowers, M. (2010). Are there bidirectional associations between depressive symptoms and C-reactive protein in mid-life women? Brain Behav. Immun., 24 (1), 96–101.10.1016/j.bbi.2009.08.005
  42. Mattina, G. F., Van Lieshout, R. J., Steiner, M. (2019). Inflammation, depression and cardiovascular disease in women: The role of the immune system across critical reproductive events. Ther. Adv. Cardiovasc. Dis., 13, doi: 10.1177/1753944719851950.10.1177/1753944719851950654565131144599
  43. Mazereeuw, G., Herrmann, N., Andreazza, A. C., Scola, G., Ma, D., Oh, P. I., Lanctōt, K. L. (2017). Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. Brain Behav. Immun., 60, 136–141.10.1016/j.bbi.2016.10.00527742581
  44. Mazza, M., Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Sheiban, I., Romagnoli, E. (2010). Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: Evidence from a meta-analysis. J. Psycho-pharmacol., 24 (12), 1785–1792.10.1177/026988110934817619965939
  45. Moryś, J. M., Bellwon, J., Adamczyk, K., Gruchała, M. (2016). Depression and anxiety in patients with coronary artery disease, measured by means of self-report measures and clinician-rated instrument. Kardiol. Pol., 74 (1), 53–60.10.5603/KP.a2015.011626101024
  46. Moylan, S., Berk, M., Dean O. M., Samuni Y., Williams, L. J., O’Neil, A., Hayley, A. C., Pasco, J. A., Anderson, G., Jacka, F. N., Maes, M. (2014). Oxidative & nitrosative stress in depression: why so much stress? Neurosci. Biobehav. Rev., 45, 46–62.10.1016/j.neubiorev.2014.05.00724858007
  47. Murray, C. J., Lopez, A. D. (2013). Measuring the global burden of disease. New Engl. J. Med., 369 (5), 448–57.10.1056/NEJMra120153423902484
  48. Myers, V., Gerber, Y., Benyamini, Y., Goldbourt, U., Drory, Y. (2012). Post-myocardial infarction depression: Increased hospital admissions and reduced adoption of secondary prevention measures — a longitudinal study. J. Psychosom. Res., 72 (1), 5–10.10.1016/j.jpsychores.2011.09.00922200515
  49. Nemeroff, C. B., Goldschmidt-Clermont, P. J. (2012). Heartache and heartbreak — the link between depression and cardiovascular disease. Nat. Rev. Cardiol., 9 (9), 526–539.10.1038/nrcardio.2012.9122733213
  50. Nezafati, M. H, Vojdanparast, M., Nezafati, P. (2015). Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atheroscl, 11 (5), 295–304.
  51. Nikkheslat, N., Zunszain, P. A, Horowitz, M. A, Barbosa, I. G., Parker, J. A., Myint, A. M., Schwarz, M. J., Tylee, A. T., Carvalho, L. A., Pariante, C. M. (2015). Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav. Immun., 48, 8–18.10.1016/j.bbi.2015.02.00225683698
  52. GBD 2016 Causes of Death Collaborators (2017). Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390 (10100), 1151–1210.
  53. Pezeshkian, M., Nouri, M., Zahraei, M., Afrasiabi, A., Abadi, N. A. (2001). Study of MDA, antioxidant vitamins, lipoproteins serum levels and anthropometry parameters in coronary artery disease patients. Med. J. Islam. Acad. Sci., 14, 5–8.
  54. Pizzi, C., Mancini, S., Angeloni, L., Fontana, F., Manzoli, L., Costa, G. M. (2009). Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin. Pharmacol. Ther., 86 (5), 527–532.10.1038/clpt.2009.12119641491
  55. Puppel, K., Kapusta, A., Kuczyñska, B. (2015). The etiology of oxidative stress in the various species of animals, a review. J. Sci. Food Agric., 95 (11), 2179–2184.10.1002/jsfa.701525418967
  56. Rees, J. N., Florang, V. R., Anderson, D. G., Doorn, J. A. (2007). Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem. Res. Toxicol., 20 (10), 1536–1542.10.1021/tx700248y17887726
  57. Del Rio, D., Stewart, A. J., Pellegrini, N. (2005). A review of recent studies on malonaldehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis., 15 (4), 316–328.10.1016/j.numecd.2005.05.003
  58. Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J. Amer. Coll. Cardiol., 76 (25), 2982–3021.10.1016/j.jacc.2020.11.010775503833309175
  59. Sanchis-Gomar, F., Perez-Quilis, C., Leischik, R., Lucia, A. (2016). Epidemiology of coronary heart disease and acute coronary syndrome. Ann. Transl. Med., 4 (13), 256.10.21037/atm.2016.06.33495872327500157
  60. Sarandol, A., Sarandol, E., Eker, S. S., Erdinc, S., Vatansever, E., Kirli, S. (2007). Major depressive disorder is accompanied with oxidative stress: Short-term antidepressant treatment does not alter oxidative antioxidative systems. Hum. Psychopharmacol., 22 (2), 67–73.10.1002/hup.82917299810
  61. Swardfager, W., Herrmann, N., Marzolini, S., Saleem, M., Farber, S. B., Kiss, A., Oh, P. I., Lanctôt, K. L. (2011). Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. J. Clin. Psychiatry, 72 (9), 1181–1188.10.4088/JCP.09m05810blu21208573
  62. Trebatická, J., Dukát, A., Ďuračková, Z., Muchová, J. (2017). Cardiovascular diseases, depression disorders and potential effects of Omega-3 fatty acids. Physiol. Res., 66 (3), 363–382.10.33549/physiolres.93343028248536
  63. Van der Kooy, K., van Hout, H., Marwijk, H., Marten, H., Stehouwer, C., Beekman, A. (2007). Depression and the risk for cardiovascular diseases: Systematic review and meta analysis. Int. J. Geriatr. Psychiatry, 22 (7), 613–626.10.1002/gps.172317236251
  64. van Melle, J. P., de Jonge, P., Spijkerman, T. A., Tijssen, J. G., Ormel, J., van Veldhuisen, D. J., van den Brink, R. H., van den Berg, M. P. (2004). Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: A meta-analysis. Psychosom. Med., 66 (6), 814–822.10.1097/01.psy.0000146294.82810.9c15564344
  65. Vaváková, M., Ďuračková, Z., Trebatická, J. (2015). Markers of oxidative stress and neuroprogression in depression disorder. Oxid. Med. Cell. Longev., 2015, 898393.10.1155/2015/898393445328026078821
  66. Vichova, T., Motovska, Z. (2013). Oxidative stress: Predictive marker for coronary artery disease. Exp. Clin. Cardiol., 18 (2), e88–e91.
  67. Voicehovskis, V. V., Margolina, J., Voicehovska, J. G, Miksons, A. (2013). Validation of the Latvian version of the Geriatric depression scale (GDS). Psychother. Psychosom., 82 (S1), 122–123.
  68. Wang, Q., Liu, D., Song, P., Zou, M. H. (2015). Tryptophan- kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci. (Landmark Ed), 20, 1116–1143.10.2741/4363491117725961549
  69. Whooley, M. A., Wong, J. M. (2013). Depression and cardiovascular disorders. Annu. Rev. Clin. Psychol., 9, 327–354.10.1146/annurev-clinpsy-050212-18552623537487
  70. Wirleitner, B., Rudzite, V., Neurauter, G., Murr, C., Kalnins, U., Erglis, A., Trusinskis, K., Fuchs, D. (2003). Immune activation and degradation of tryptophan in coronary heart disease. Eur. J. Clin. Invest., 33 (7), 550–554.10.1046/j.1365-2362.2003.01186.x12814390
  71. World Health Organization, Mendis, S., Puska, P., Norrving, B. (eds.) (2011). Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization. 155 pp.
  72. Yekehtaz, H., Farokhnia, M., Akhondzadeh, S. (2013). Cardiovascular considerations in antidepressant therapy: An evidence-based review. J. Tehran Heart Cent., 8 (4), 169–176.
  73. Zuo, H., Ueland, P. M., Ulvik, A., Eussen, S. J., Vollset, S. E., Nygård, O., Midttun, Ø., Theofylaktopoulou, D., Meyer, K., Tell, G. S. (2016). Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality. Amer. J. Epidemiol., 183 (4), 249–258.10.1093/aje/kwv242475328326823439
DOI: https://doi.org/10.2478/prolas-2022-0028 | Journal eISSN: 2255-890X | Journal ISSN: 1407-009X
Language: English
Page range: 181 - 187
Submitted on: Apr 28, 2021
Accepted on: Dec 5, 2021
Published on: Jun 2, 2022
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2022 Tarass Ivaščenko, Vladimirs V. Voicehovskis, Oskars Kalējs, Jūlija G. Voicehovska, Andrejs Šķesters, Natālija Pahomova, Aivars Lejnieks, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.